Status:
COMPLETED
Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Measles
Mumps
Eligibility:
All Genders
12-23 years
Phase:
PHASE3
Brief Summary
This study will compare three consistency lots of ProQuad to each other as well as to M-M-R II and Varivax, administered concomitantly at different injection sites, with respect to immunogenicity, saf...
Eligibility Criteria
Inclusion
- In good health
- Negative clinical history of measles, mumps, rubella, varicella, and zoster
Exclusion
- Previous receipt of measles, mumps, rubella and/or varicella vaccine either alone or in combination
- Any immune impairment or deficiency
- Exposure to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior to vaccination
- Vaccination with an inactive vaccine with in the past 14 days
- Vaccination with a live vaccine within the past 30 days
Key Trial Info
Start Date :
March 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2001
Estimated Enrollment :
3927 Patients enrolled
Trial Details
Trial ID
NCT00985153
Start Date
March 1 2000
End Date
May 1 2001
Last Update
November 23 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.